Bone drug Zometa flops in breast cancer study

Dec 09, 2010 By MARILYNN MARCHIONE , AP Medical Writer

(AP) -- Doctors are reporting a stunning setback for a promising new approach for fighting breast cancer.

A large study found that the bone-building drug Zometa (zow-MAY-tuh) did not prevent the return of cancer or improve survival in women with early or mid-stage disease.

Zometa did seem to help women at least five years past or over 60. The drug's maker, Novartis AG, is considering further tests in those women. Studies also are testing similar drugs, bisphosphonates like Fosamax and Boniva, to see if they help prevent .

Zometa is currently used to treat cancer that has already spread to the bone. The new study will not change that or affect the use of other similar drugs for .

Explore further: Discovery could lead to new cancer treatment

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Novel cancer drug has potential, study reports

Nov 12, 2010

(PhysOrg.com) -- Monthly injections of the drug in breast cancer patients whose disease had spread to the bone helped reduce pain and prevent complications with less toxicity than current treatments.

FDA warns of fractures with osteoporosis drugs

Oct 13, 2010

(AP) -- Government health officials warned doctors and patients Wednesday about an increased risk of thigh fractures with a widely used group of bone-strengthening drugs.

Breast cancer study halted

Jun 20, 2007

The U.S. National Cancer Institute halted a $100 million study of drugs designed to prevent breast cancer in women at risk for the disease.

Recommended for you

Discovery could lead to new cancer treatment

9 hours ago

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications ...

Is the HPV vaccine necessary?

16 hours ago

As the school year starts in full swing many parents wonder if their child should receive the HPV vaccine, which is recommended for girls ages 11-26 and boys 11-21. There are a lot of questions and controversy around this ...

User comments : 0